Gastrointestinal varices secondary prevention: Difference between revisions
Created page with "__NOTOC__ {{Gastrointestinal varices}} {{CMG}}; {{AE}} ==Overview== ==Secondary Prevention== ==References== {{reflist|2}}" |
No edit summary |
||
| (5 intermediate revisions by the same user not shown) | |||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Gastrointestinal varices}} | {{Gastrointestinal varices}} | ||
{{CMG}}; {{AE}} | {{CMG}}; {{AE}} {{HK}} | ||
==Overview== | ==Overview== | ||
[[Secondary prevention]] of gastrointestinal varices involves [[Prevention (medical)|prevention]] of rebleeding. The choice of method chosen for [[secondary prevention]] of gastrointestinal varices depends upon the condition of the patient, medication history and response to treatment. Methods used for [[secondary prevention]] include the use of [[beta blockers]], band ligation, [[Transjugular intrahepatic portosystemic shunt|TIPS]] and [[liver transplantation]]. | |||
==Secondary Prevention== | ==Secondary Prevention== | ||
[[Secondary prevention]] of gastrointestinal varices involves [[Prevention (medical)|prevention]] of rebleeding. The following options are available, according to the condition of the patient:<ref name="pmid17060770">{{cite journal |vauthors=Krige JE, Kotze UK, Bornman PC, Shaw JM, Klipin M |title=Variceal recurrence, rebleeding, and survival after endoscopic injection sclerotherapy in 287 alcoholic cirrhotic patients with bleeding esophageal varices |journal=Ann. Surg. |volume=244 |issue=5 |pages=764–70 |year=2006 |pmid=17060770 |pmc=1856595 |doi=10.1097/01.sla.0000231704.45005.4e |url=}}</ref><ref name="pmid15925423">{{cite journal |vauthors=de Franchis R |title=Evolving consensus in portal hypertension. Report of the Baveno IV consensus workshop on methodology of diagnosis and therapy in portal hypertension |journal=J. Hepatol. |volume=43 |issue=1 |pages=167–76 |year=2005 |pmid=15925423 |doi=10.1016/j.jhep.2005.05.009 |url=}}</ref><ref name="urlEsophageal varices: from appearance to rupture; natural history and prognostic indicators | SpringerLink">{{cite web |url=https://link.springer.com/chapter/10.1007/978-94-007-1042-9_17 |title=Esophageal varices: from appearance to rupture; natural history and prognostic indicators | SpringerLink |format= |work= |accessdate=}}</ref><ref name="pmid12939586">{{cite journal |vauthors=D'Amico G, De Franchis R |title=Upper digestive bleeding in cirrhosis. Post-therapeutic outcome and prognostic indicators |journal=Hepatology |volume=38 |issue=3 |pages=599–612 |year=2003 |pmid=12939586 |doi=10.1053/jhep.2003.50385 |url=}}</ref> | |||
'''Time to start secondary prophylaxis''' | |||
*Secondary prophylaxis should start as soon as possible from day 6 of the index variceal bleeding episode | |||
*The time of initiation of secondary prophylaxis should be recorded. | |||
'''Patients with cirrhosis who have not received primary prophylaxis''' | |||
*In these patients, a combination of [[beta blockers]] and endoscopic band ligation may be used as a measure for secondary prophylaxis | |||
*Rebledding risk may be predicted by using the patient's response to pharmacological therapy as a [[prognostic]] factor | |||
'''Patients with cirrhosis who are on beta blockers for primary prevention and bleed''' | |||
*Band ligation should be considered in addition to [[beta blockers]] | |||
'''Patients who have contraindications or intolerance to beta blockers''' | |||
*Band ligation is the treatment of choice for [[Prevention (medical)|prevention]] of rebleeding | |||
'''Patients who fail endoscopic and pharmacological treatment for prevention of rebleeding''' | |||
*[[Transjugular intrahepatic portosystemic shunt|TIPS]] or surgical shunts (distal [[Splenorenal ligament|splenorenal]] shunt or 8 mm H-graft) are effective for those with Child class A/B [[cirrhosis]] | |||
*In non-surgical candidates, [[Transjugular intrahepatic portosystemic shunt|TIPS]] is the sole option available | |||
*Transplantation is associated with good long-term outcomes in Child class B/C [[cirrhosis]] and should be considered | |||
*TIPS serves as a bridge to transplantation | |||
'''Patients who have bled from isolated gastric varices, type 1 (IGV1) or gastro-oesophageal varices, type 2 (GOV 2)''' | |||
*N-butyl-[[cyanoacrylate]] | |||
*[[Transjugular intrahepatic portosystemic shunt|TIPS]] | |||
*[[Beta blockers]] | |||
'''Patients who have bled from gastro-esophageal varices, type 1 (GOV 1)''' | |||
*May be treated via band ligation of [[esophageal]] varices with [[cyanoacrylate]] or [[beta blockers]] | |||
'''Patients who have bled from portal hypertensive gastropathy''' | |||
*[[Beta blockers]] to prevent recurrent bleeding | |||
'''Patients in whom beta blockers are contraindicated or fail and who cannot be managed by non-shunt therapy''' | |||
*[[Transjugular intrahepatic portosystemic shunt|TIPS]] | |||
*Surgical shunts | |||
==References== | ==References== | ||
{{reflist|2}} | {{reflist|2}} | ||
Latest revision as of 18:39, 4 January 2018
|
Gastrointestinal varices Microchapters |
|
Differentiating Gastrointestinal varices from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Gastrointestinal varices secondary prevention On the Web |
|
American Roentgen Ray Society Images of Gastrointestinal varices secondary prevention |
|
Risk calculators and risk factors for Gastrointestinal varices secondary prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Syed Hassan A. Kazmi BSc, MD [2]
Overview
Secondary prevention of gastrointestinal varices involves prevention of rebleeding. The choice of method chosen for secondary prevention of gastrointestinal varices depends upon the condition of the patient, medication history and response to treatment. Methods used for secondary prevention include the use of beta blockers, band ligation, TIPS and liver transplantation.
Secondary Prevention
Secondary prevention of gastrointestinal varices involves prevention of rebleeding. The following options are available, according to the condition of the patient:[1][2][3][4]
Time to start secondary prophylaxis
- Secondary prophylaxis should start as soon as possible from day 6 of the index variceal bleeding episode
- The time of initiation of secondary prophylaxis should be recorded.
Patients with cirrhosis who have not received primary prophylaxis
- In these patients, a combination of beta blockers and endoscopic band ligation may be used as a measure for secondary prophylaxis
- Rebledding risk may be predicted by using the patient's response to pharmacological therapy as a prognostic factor
Patients with cirrhosis who are on beta blockers for primary prevention and bleed
- Band ligation should be considered in addition to beta blockers
Patients who have contraindications or intolerance to beta blockers
- Band ligation is the treatment of choice for prevention of rebleeding
Patients who fail endoscopic and pharmacological treatment for prevention of rebleeding
- TIPS or surgical shunts (distal splenorenal shunt or 8 mm H-graft) are effective for those with Child class A/B cirrhosis
- In non-surgical candidates, TIPS is the sole option available
- Transplantation is associated with good long-term outcomes in Child class B/C cirrhosis and should be considered
- TIPS serves as a bridge to transplantation
Patients who have bled from isolated gastric varices, type 1 (IGV1) or gastro-oesophageal varices, type 2 (GOV 2)
- N-butyl-cyanoacrylate
- TIPS
- Beta blockers
Patients who have bled from gastro-esophageal varices, type 1 (GOV 1)
- May be treated via band ligation of esophageal varices with cyanoacrylate or beta blockers
Patients who have bled from portal hypertensive gastropathy
- Beta blockers to prevent recurrent bleeding
Patients in whom beta blockers are contraindicated or fail and who cannot be managed by non-shunt therapy
- TIPS
- Surgical shunts
References
- ↑ Krige JE, Kotze UK, Bornman PC, Shaw JM, Klipin M (2006). "Variceal recurrence, rebleeding, and survival after endoscopic injection sclerotherapy in 287 alcoholic cirrhotic patients with bleeding esophageal varices". Ann. Surg. 244 (5): 764–70. doi:10.1097/01.sla.0000231704.45005.4e. PMC 1856595. PMID 17060770.
- ↑ de Franchis R (2005). "Evolving consensus in portal hypertension. Report of the Baveno IV consensus workshop on methodology of diagnosis and therapy in portal hypertension". J. Hepatol. 43 (1): 167–76. doi:10.1016/j.jhep.2005.05.009. PMID 15925423.
- ↑ "Esophageal varices: from appearance to rupture; natural history and prognostic indicators | SpringerLink".
- ↑ D'Amico G, De Franchis R (2003). "Upper digestive bleeding in cirrhosis. Post-therapeutic outcome and prognostic indicators". Hepatology. 38 (3): 599–612. doi:10.1053/jhep.2003.50385. PMID 12939586.